• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Directories » FDA Approved Drugs » Corvert Injection (ibutilide fumarate injection)

AND
  • A
  • B
  • C
  • D
  • E
  • F
  • G
  • H
  • I
  • J
  • K
  • L
  • M
  • N
  • O
  • P
  • Q
  • R
  • S
  • T
  • U
  • V
  • W
  • X
  • Y
  • Z

Corvert Injection (ibutilide fumarate injection)

  • Profile

Profile

Contact Information

Contact: Pfizer
Website: https://www.pfizer.com/products-list?letter=C

Currently Enrolling Trials

    Show More

    General Information

    Corvert (ibutilide fumarate injection) is an antiarrhythmic drug with predominantly class III (cardiac action potential prolongation) properties.

    Corvert is specifically indicated for the rapid conversion of atrial fibrillation or atrial flutter of recent onset to sinus rhythm. Patients with atrial arrhythmias of longer duration are less likely to respond to Corvert.

    The recommended initial dose of Corvert is in the table below.  Ibutilide infusion should be stopped as soon as the presenting arrhythmia is terminated or in the event of sustained or non-sustained ventricular tachycardia, or marked prolongation of QT or QTc.

    Second Infusion: If the arrhythmia does not terminate within 10 minutes after the end of the initial infusion, a second 10-minute infusion of equal strength may be administered 10 minutes after completion of the first infusion.

    Patient Weight Initial Infusion (over 10 minutes)
    60 kg (132 lb)
    or more
    One vial
      (1 mg ibutilide fumarate)
    Less than 60 kg
    (132 lb)
    0.1 mL/kg
      (0.01 mg/kg ibutilide fumarate)

     

    Mechanism of Action

    Corvert (ibutilide fumarate injection) prolongs action potential duration in isolated adult cardiac myocytes and increases both atrial and ventricular refractoriness in vivo, ie, class III electrophysiologic effects. Voltage clamp studies indicate that Corvert, at nanomolar concentrations, delays repolarization by activation of a slow, inward current (predominantly sodium), rather than by blocking outward potassium currents, which is the mechanism by which most other class III antiarrhythmics act. These effects lead to prolongation of atrial and ventricular action potential duration and refractoriness, the predominant electrophysiologic properties of Corvert in humans that are thought to be the basis for its antiarrhythmic effect.

    Side Effects

    Adverse effects associated with the use of Corvert may include, but are not limited to, the following:

    • nausea
    • cardiovascular, including sustained polymorphic ventricular tachycardia and non-sustained polymorphic ventricular tachycardia

    Clinical Trial Results

    The results of two, large, placebo-controlled, double-blind and randomized clinical trials demonstrated that, compared with placebo, Corvert Injection successfully and rapidly converted atrial fibrillation and flutter to normal rhythm. In a third study conducted in Europe, Covert compared favorably with another intravenous antiarrhythmic agent currently unavailable in the United States

     

    Approval Date: 1995-12-01
    Company Name: Pfizer
    Back to Listings

    Upcoming Events

    • 16Feb

      Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

    • 21May

      WCG MAGI Clinical Research Conference – 2023 East

    Featured Products

    • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

      Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    • Surviving an FDA GCP Inspection

      Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

    Featured Stories

    • Revamp-360x240.png

      Califf Calls for Major Evidence Generation Revamp, Experts’ Opinions Differ

    • AskTheExpertsGreen-360x240.png

      Ask the Experts: Managing Investigational Products

    • SurveywBlueBackground-360x240.png

      Survey Outlines Site Challenges, Successes on Diversity

    • PatientCentricity-360x240.png

      Site Spotlight: DM Clinical Shows Patient Centricity Doesn’t Have to Break the Bank

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell or Share My Data

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 617.948.5100 – Toll free 866.219.3440

    Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing